The Impact of Antithrombotic Regimens on Clinical Outcomes After Endovascular Intervention and Bypass Surgery for Infrapopliteal Artery Disease

Amol Gupta, Michael S. Lee, Kush Gupta, Vinod Kumar, Sarath Reddy

Abstract
Endovascular intervention and bypass surgery are the main options of treatments for infrapopliteal artery disease. Although post-intervention treatment with antiplatelet (AP) and/or anticoagulant (AC) drugs has reduced morbidity and mortality rates from cardiovascular complications, the ideal antithrombotic treatment regimen is unknown. The aim of this review was to compare the efficacy and safety of various anticoagulation and/or AP therapy regimens in patients undergoing below-knee endovascular treatment for infrapopliteal artery disease. We reviewed published literature in PubMed and Google Scholar, and Cochrane, evaluating efficacy and safety outcomes after antithrombotic treatment following endovascular intervention or bypass surgery in patients with infrapopliteal artery disease. We extracted relevant efficacy and safety data with related statistics from each study. We found that AP treatment should be administered to patients receiving endovascular therapy or bypass.

We did not find superior effects for dual AP treatment (DAPT) over mono-AP therapy (MAPT) for endovascular intervention or bypass surgery with venous graft, suggesting that MAPT suffices for these groups. Also, aspirin + clopidogrel was effective over aspirin alone for prosthetic, but not venous graft, albeit higher non-severe bleeding incidences, suggesting a potential benefit of this regime for below-knee prosthetic graft. AP + AC yielded superior results compared to AP following endovascular procedure and bypass surgery, suggesting the potential benefit of this regime in the absence of contraindications. More prospective studies with large number of patients are warranted to identify the best treatment for infrapopliteal artery diseases.

Keywords: Antiplatelet; Anticoagulant; Infrapopliteal artery disease; Peripheral artery disease; Endovascular intervention; Bypass surgery

Introduction
Critical limb ischemia (CLI) represents the terminal stage of obstructive, atherosclerotic, peripheral arterial disease (PAD) [1, 2]. Foot ulceration with tissue loss and gangrene are some of the manifestations of CLI, which may lead to major amputation if the affected arteries are not promptly revascularized [3]. Infrapopliteal arterial disease, alone or combined with other PAD, is the leading cause of CLI [4]. Despite advances in treatment of PAD, treatment of infrainguinal arterial disease has several unique challenges that complicate the treatment compared to more proximal lower extremity disease [5, 6]. These include small vessel size, prevalence of diffuse multilevel and multivessel calcific disease, and fewer suitable target vessels for bypass, particularly in patients with diabetes or renal failure or both [7]. In addition, the rate of restenosis may reach levels up to 50% within 1 year following endovascular intervention for PAD [8-10]. Restenosis following endovascular intervention may be even higher and more challenging for patients with infrapopliteal artery diseases [11-13]. Similarly, graft occlusion rates following bypass surgery have been ranging from 15% for venous graft and 20% for prosthetic grafts, and this ratio dramatically increases for below-knee grafts [14, 15].

Although several pharmacologic and non-pharmacologic approaches have been evaluated to improve the results of endovascular intervention and bypass surgery, there is no consensus or verified therapeutic approach, which might be partly due to the complex heterogeneity of these patients [16, 17]. In addition, the benefits of antithrombotic treatment for patients who undergo endovascular procedure for infrapopliteal diseases or lower extremity bypass to below-knee targets remain unclear. There are ample studies that reported the effects of antiplatelets (APs) and anticoagulants (ACs) on the clinical outcome following endovascular or bypass surgery for femoropopliteal artery segment and were reported in Cochrane system as reviewed by Vos et al [18]. However, similar studies for infrapopliteal artery are scarce in the literature. The recommendations of antithrombotic treatment following endovascular or surgical intervention for femoropopliteal artery diseases should not be expanded to infrapopliteal artery diseases. The importance of evaluating the effects of antithrombotic treatment following infrapopliteal artery intervention stems from the fact that...
infrapopliteal arteries have smaller diameter, thinner arterial muscular wall, and are more prone to lower pulsatile flow than femoropopliteal artery segment [19, 20]. High patency rates in the infrapopliteal arteries or below-knee grafts are vital for maximized perfusion for tissue healing following intervention and the delivery of the drug following intervention plays a vital role in this process. The differences between the endovascular successes of drug-coated balloons were remarkable when used for femoropopliteal and infrapopliteal arteries where there was much success for the femoropopliteal arteries probably due to the aforementioned reasons and as reviewed [20]. With the expanded use of endovascular intervention and the probability of high restenosis rates in the infrapopliteal arteries than femoropopliteal arteries, it is essential to further investigate the effects of antithrombotic treatment following intervention for infrapopliteal artery. This is fundamental increase in drug delivery to this arterial segment consequently the outcome of the intervention.

The aim of this study was to gather and evaluate relevant literature for patients undergoing below-knee endovascular and bypass surgery treatment with regards to the efficacy and safety of various anticoagulation and AP therapy regimens. We also aimed to highlight current deficiency of information that interferes with sound treatment recommendations for this group of patients.

**Literature Search**

**Study design**

A standardized electronic literature search in English was conducted in PubMed and Google Scholar, and Cochrane for key terms including “clinical trial”, “prospective”, “retrospective”, “angioplasty”, “endovascular”, “revascularization”, “bypass”, “antiplatelet”, “anticoagulants”, “platelet aggregation inhibition”, “below the knee”, “infrapopliteal”, “peroneal”, “crural”, “tibial”, “clinical trial”, “prospective”, “retrospective”, “peripheral artery disease”, and individual AP or AC drug name or category such as “aspirin”, “clopidogrel”, “cilostazol”, and “warfarin”.

**Selection criteria**

The studies included in this review met the following criteria: 1) Designed explicitly for infrapopliteal arteries, or we were able to extract the numbers of patients and outcomes for infrapopliteal arteries if the study contains other peripheral artery segment(s); 2) Studies that contain at least 70% of the injuries related to infrapopliteal arteries; 3) Designed to evaluate the effects of AP and/or AC on particular endpoints in a comparative manner (comparing two treatment groups); 4) APs and ACs were administered following endovascular intervention or bypass surgery (antithrombotic was not only applied to determine their effects during the surgery; 5) The study recorded significant outcomes such as patency, restenosis, reocclusion, target limb revascularization (TLR), limb salvage, major amputation (above ankle area); major adverse cardiac events (MACEs) (any record of cardiovascular death, myocardial infarction, angina, stroke, hospitalization for heart failure), all-cause mortality, and minor or major bleeding (major bleeding, intracranial hemorrhage, requiring blood transfusion, or any combination of these parameters); 6) Patients were followed up at least 3 months or 1 month following endovascular or bypass, respectively for endovascular and bypass; 7) Included at least around 10 cases/group; and 8) Study focus was either randomized clinical trial (RCT), prospective cohort, or retrospective (no collection of case control studies).

We reviewed the titles and abstracts of articles that we identified in the literature as potentially suitable for inclusion in the review. Then, we confirmed the eligibility of the manuscript for inclusion in this systematic review. We targeted the evaluation of four different antithrombotic therapeutic groups: mono-AP therapy (MAPT), dual-AP therapy (DAPT), AC, and AP + AC. We extracted the relevant data that evaluated effectiveness and safety of the therapeutic groups along with their relevant statistics from each study. Data were then categorized according to similarity of treatment regimen and approach (endovascular or bypass surgery). Our search resulted in six publications for endovascular intervention (100% of the cases were for infrapopliteal arteries). With regard to studies involving bypass surgery, we found eight articles that matched the inclusion criteria (seven articles included 100% of the cases with grafts crossed the knee and one study with 70% of the grafts crossed the knee).

**Literature Review**

**The effects of AP and AC treatment following endovascular interventions in infrapopliteal artery disease**

We found studies that evaluated MAPT, DAPT, and ACs, but there were no studies evaluating AP + AC. Table 1 illustrates the antithrombotic drug groups that were used in the studies included in the review along with their mechanism of action.

**Mono-AP and dual-AP therapy**

Table 2 shows the effects of MAPT and DAPT on many effectiveness-related parameters such as patency, restenosis, occlusion, TLR, major amputation, MACEs, and all-cause mortality, as well as bleeding, the safety-related parameter [21-23]. We found only one study that evaluated MAPT effect (lipo-ecraprost) compared to placebo that showed no superior effect of lipo-ecraprost over placebo for amputation [21]. DAPT treatment with aspirin + cilostazol did not show any significant effects over MAPT effects for restenosis, major amputation, MACE mortality [23]. However, the data from Soga et al [22] showed the value of the addition of cilostazol to the platelet treatment regime by improving restenosis, reocclusion and TLR parameters to the platelet treatment regime. Also, Lejay et al [24] showed the significance of the compliance of the patients with their described anti-platelet treatment schedule.
which was particularly important for the patency of the arterial segment following endovascular procedure. There were no significant differences between the groups for the bleeding events for studies that reported this outcome [22, 23].

### Mono-AP and mono-AP plus AC therapy

Table 2 presents the effectiveness of MAPT versus AP + AC and the safety (bleeding) differences between the two groups [21-26]. The two studies were by the same group although one study was explicitly performed to evaluate the treatment effects on below-knee arteries [25], while the other included data for both femoropopliteal and infrapopliteal arteries [26]. The results were consistent regarding the significant improvement of reocclusion rates in response to batroxobin plus aspirin over aspirin for the infrapopliteal arterial segments. Bleeding events were also comparable between the two groups.

### The effects of antithrombotic treatment following below-knee bypass surgery

Table 3 shows the effectiveness and safety of MAPT and DAPT [27-34]. Ticlopidine showed significant superior effects over placebo for graft patency and amputation [27]. DAPT studies suggested significant improvement of patency in prosthetic grafts, but not in venous grafts when compared to no-treatment group [29]. Consistently, patients treated with DAPT had significantly higher patency rates as well as amputation rate but only for prosthetic grafts when compared with MAPT [28]. Bleeding incidences were significantly higher in DAPT group compared to MAPT, albeit the severe and fatal bleeding incidences were comparable between the two groups [28].

### Mono-AP and mono-AP plus AC therapy

We found one study that compared the two groups [30]. AP + AC was significantly superior than MAPT for patency and limb salvage rates. Hematoma, but not other bleeding events, was significantly higher in AP + AC.

### AC therapy

Table 3 shows three studies [31-33] that evaluated the outcome of different therapeutic regime of ACs. Direct oral ACs were suggested to have similar outcomes to traditional heparin-warfarin treatment for polytetrafluoroethylene (PTFE) grafts [31]. Low molecular weight heparin (LMWH) was superior to dextran for MACES [32] and to unfractionated heparin for graft patency following bypass surgery. Therapeutic warfarin (international randomized ratio (INR) ≥ 2.0) was superior to subtherapeutic warfarin (INR ≤ 1.9) for graft patency and survival, albeit bleeding was relatively greater in therapeutic group [34].

### Discussion

AP treatment seems to be essential and routinely used in the post-operative treatment of endovascular and bypass groups. We did not find superior effects for DAPT over MAPT for endovascular intervention or bypass surgery with venous graft,
| Study/type | Procedure | Treatment/follow-up duration | Endpoints | Treatment groups and endpoint rates | Significance | Notes |
|------------|-----------|-----------------------------|-----------|-------------------------------------|--------------|-------|
| Placebo versus MAPT | Nehler [21], 2007/RCT | n.m. Placebo vs. lipoecraprost (6 months) | Major amputation | Placebo (n = 41) vs. lipo-ecraprost (n = 30) | n.s. | 1) Included data for both bypass surgery and endovascular intervention, 2) major amputation was the only specific data reported for endovascular intervention. For combined results (bypass and endovascular), there were no differences for mortality rates or MCE |
| MAPT vs. DAPT | Soga [23], 2017/RCT | Balloon angioplasty Aspirin vs. aspirin + cilostazol (3 months) | Aspirin (100 mg/day) (n = 25) vs. Aspirin (100 mg/day) + cilostazol | Restenosis 81% vs. 82%, Major amputation 4% vs. 4%, MACEs 4% vs. 4%, Mortality 0% vs. 0%, Bleeding events 0% vs. 0% | n.s. | |
| Antiplatelet group vs. antiplatelet group | Soga [22], 2012/retrospective (Angioplasty), selection of an EVT approach was left to the discretion of the operator | Non-cilostazol group vs. cilostazol group (3 months) | Non-cilostazol group (n = 31) vs. Cilostazol group (n = 32) | Restenosis 86% vs. 56.8%, Reocclusion 42.1% vs. 20.50%, TLR 40.1% vs. 27.50%, MACEs 0% vs. 0%, Mortality 0% vs. 0%, Bleeding events 0% vs. 0% | P = 0.001 vs. 0.02 vs. 0.01, n.s. vs. n.s. | Non-cilostazol group (aspirin (n = 14), thienopyridine (n = 2) alone, aspirin + thienopyridine (n = 15), cilostazol group (cilostazol (n = 3), aspirin + cilostazol (n = 16), thienopyridine + cilostazol (n = 3), aspirin + thienopyridine + cilostazol (n = 10)) |
| | Lejay [24], 2013/retrospective Angioplasty with or without stenting | Aspirin + clopidogrel, followed by long-term clopidogrel (non-compliant) vs. aspirin + clopidogrel, followed by long-term clopidogrel (compliant); mean follow-up (30.3 ± 20.2 months) | Aspirin + clopidogrel, followed by long-term clopidogrel (non-compliant) (n = 15) vs. Aspirin + clopidogrel, followed by long-term clopidogrel (compliant) (n = 10) | Restenosis 42% vs. 18%, Reocclusion 62% vs. 40%, TLR 40% vs. 20%, MACEs 0% vs. 0%, Mortality 0% vs. 0%, Bleeding events 0% vs. 0% | 1) Treatment doses were not specified, 2) statistics presented here for univariate analysis, 3) infrapopliteal procedure had a negative effect on non-compliant group, 4) bleeding events were not evaluated |
### Table 2. Antiplatelets and Anticoagulants Treatments Following Endovascular Intervention - (continued)

| Study/type | Procedure | Treatment/follow-up duration | Endpoints                  | Treatment groups and endpoint rates                                                                 | Significance | Notes                                                                                                                                 |
|------------|-----------|------------------------------|----------------------------|------------------------------------------------------------------------------------------------------|--------------|------------------------------------------------------------------------------------------------------------------------------------|
|            |           |                              | Survival                   | n.m.                                                                                                  | n.m.         | n.s.                                                                                                                                 |
|            |           |                              | Primary patency            | n.m.                                                                                                  | n.m.         | P < 0.01                                                                                                                            |
|            |           |                              | Limb salvage               | n.m.                                                                                                  | n.m.         | n.s.                                                                                                                                 |
| MAPT vs. anticoagulant |           |                              |                            |                                                                                                       |              |                                                                                                                                 |
| Wang [26], 2011/RCT |           | Angioplasty (intraluminal/subintimal) | Aspirin vs. aspirin + batroxobin (3 months) | Aspirin (100 mg/d) for minimum 12 months if no side effects (n = 206)                                | P < 0.01     | 1) Included combined data for infrapopliteal and femoropopliteal artery segments, 2) subgroup analysis for infrapopliteal was performed for reocclusion only, 3) for the comparison for combined infrapopliteal and femoropopliteal surgeries: a) rates were better for cumulative rate of major amputation or death and for limb salvage and survival rates, b) there were no differences for restenosis, reocclusion, major amputation, and mortality, and C) no differences for bleeding events |
| Wang [25], 2010/RCT (pilot) |           | Angioplasty (intraluminal/subintimal) | Aspirin vs. aspirin + batroxobin (12 months) | Aspirin (100 mg/d) for 12 months from admission if no side effects (n = 26) Aspirin (control group) + batroxobin (5 IU/0.5 mL), two doses before and four doses after the procedure (n = 173) | P = 0.0026   | 1) No differences for serious bleeding events, 2) amputation-free rates are for major and minor amputation |

Reocclusion: 42.7% 27.7%  P = 0.0026

Restenosis/reocclusion: 45% 26%  P = 0.0353

Limb salvage rate: 92.3% 96.2%  n.s.

Amputation: 15.4% 15.4%  n.s.

RCT: randomized clinical trial; MAPT: mono-antiplatelet treatment; DAPT: dual antiplatelet treatment; EVT: endovascular therapy; TLR: target lesion revascularization; MACE: major adverse cardiac event; MCE: major cardiac event; n.s.: not significant; n.m.: not measured.
### Table 3. Antiplatelet and Anticoagulant Treatments Following Below-Knee Bypass Surgery

| Study/type | Procedure                  | Treatment/follow-up duration | Endpoints                  | Treatment groups and endpoint rates | Significance | Notes                                                                 |
|------------|----------------------------|------------------------------|----------------------------|-------------------------------------|--------------|-----------------------------------------------------------------------|
| Placebo vs. MAPT | Venous grafts | Placebo vs. ticlopidine (24 months) | Primary patency | Placebo (325 mg/day) (n = 121) | 51% | 66% | P = 0.02 |
| Becquemin [27], 1997/RCT | Venous grafts | Placebo vs. ticlopidine (24 months) | Secondary patency | Ticlopidine (250 mg twice a day for 24 months) (n = 122) | 55% | 69% | P = 0.03 |
| | | | Cumulative secondary patency | | | | P = 0.02 |
| | | | Amputation | | 7% | 2% | P = 0.05 |
| | | | Mortality rate | | 15% | 15% | n.s. |
| | | | MACEs | | 12% | 10% | n.s. |
| | | | Bleeding events | | 3% | 1.64% | n.s. |
| | | | Other bleeding events | | 1.70% | 0.8% | n.s. |
| | | | Notes | | 100% of the bypass grafts were below the knee |
| No treatment vs. DAPT | Venous and prosthetic grafts | No treatment vs. aspirin + dipyridamole (12 months) | Graft patency | No treatment (total grafts, n = 70; autogenous grafts, n = 44; prosthetic grafts, n = 26) | 68% | 83% | n.s. |
| Clyne [29], 1987/RCT | Venous and prosthetic grafts | No treatment vs. aspirin + dipyridamole (12 months) | Autogenous | | 73% | 83% | n.s. |
| | | | Prosthetic graft | | 53% | 85% | P = 0.005 |
| | | | Amputation (all grafts) | | 17% | 10% | n.s. |
| | | | Death (all grafts) | | 11% | 14% | n.s. |
| | | | MACEs (all grafts) | | 3% | 6% | n.s. |
| | | | Notes | | 1) For patency, 100% of the grafts were below the knee as stratified by the study, 2) for amputation, death, and MCE, 80% of the grafts were infrapopliteal |
| MAPT vs. DAPT | Venous and prosthetic grafts | Aspirin vs. aspirin + clopidogrel (24 months) | Graft occlusion | Placebo + aspirin (75 - 100 mg/day) (total grafts, n = 426; venous grafts, n = 301; prosthetic grafts, n = 125) | | | |
| Belch [28], 2010/RCT | Venous and prosthetic grafts | Aspirin vs. aspirin + clopidogrel (24 months) | | Aspirin (same as control) + clopidogrel (75 mg/day) (total grafts, n = 425; venous grafts, n = 297; prosthetic grafts, n = 128) | 100% of the grafts were below the knee, bleeding follow-up duration was not specified |
Table 3. Antiplatelet and Anticoagulant Treatments Following Below-Knee Bypass Surgery - (continued)

| Study/type | Procedure | Treatment/follow-up duration | Endpoints | Treatment groups and endpoint rates | Significance | Notes |
|------------|-----------|------------------------------|-----------|------------------------------------|--------------|-------|
|            | All grafts | 22.77%                       | 21.88%    | HR 0.94 (0.71 - 1.25)              |              |       |
|            | Venous     | 12.62%                       | 17.51%    | HR 1.45 (0.95 - 2.20)              |              |       |
|            | Prosthetic | 47.20%                       | 32.03%    | HR 0.63 (0.42 - 0.93), P = 0.021  |              |       |
|            |            |                              |           |                                    |              |       |
| Amputation | All grafts | 10.56%                       | 7.29%     | HR 0.68 (0.43 - 1.08)              |              |       |
|            | Venous     | 6.98%                        | 6.40%     | HR 0.93 (0.50 - 1.72)              |              |       |
|            | Prosthetic | 19.20%                       | 9.38%     | HR 0.48 (0.24 - 0.96), P = 0.034  |              |       |
| Death      | All grafts | 3.99%                        | 5.65%     | HR 1.44 (0.77 - 2.68)              |              |       |
|            | Venous     | 4.32%                        | 6.06%     | HR 1.43 (0.70 - 2.91)              |              |       |
|            | Prosthetic | 3.20%                        | 4.69%     | HR 1.51 (0.42 - 5.33)              |              |       |
| Bleeding   | (n = 422)  | (n = 426)                     |           |                                     |              |       |
|            | Total      | 7.04%                        | 16.67%    | P < 0.001                          |              |       |
|            | Severe     | 1.18%                        | 2.12%     | n.s.                               |              |       |

Antiplatelet vs. antiplatelet + anticoagulant

Sarac [30], 1998/RCT: Venous grafts

| Procedure | Treatment | Study | Endpoints | Significance | Notes |
|-----------|-----------|-------|-----------|--------------|-------|
| Aspirin vs. aspirin + warfarin (up to 36 months) | Aspirin (325 mg/day) (n = 24) | Aspirin (same as control) + warfarin (adjusted to maintain INR between 2 and 3) (n = 32) | 1) > 90% of the bypass grafts were below the knee, 2) mortality and bleeding were measured perioperatively (1 month from operation), 3) other parameters are measured as cumulative for 3 years | P = 0.04 |
| Cumulative primary patency | 51% | 74% | P = 0.04 |
| Cumulative primary assisted patency | 56% | 77% | P = 0.05 |
| Cumulative secondary patency | 56% | 81% | P = 0.02 |
Table 3. Antiplatelet and Anticoagulant Treatments Following Below-Knee Bypass Surgery - (continued)

| Study/type | Procedure | Treatment/follow-up duration | Endpoints | Treatment groups and endpoint rates | Significance | Notes |
|------------|-----------|-------------------------------|-----------|-------------------------------------|--------------|-------|
| Anticoagulant vs. anticoagulant | | | | **Cumulative limb salvage rate** | | **P = 0.01** |
| | | | | 31% | 81% | |
| | | | | Mortality rate | | n.s. |
| | | | | 0% | 3% | |
| | | | | Bleeding events (hematoma) | | 0.004 |
| | | | | 4% | 32% | |
| | | | | Other bleeding events | | n.s. |
| | | | | 17% | 15.63% | |
| Aurshina [31], 2018/retrospective | PTFE graft | Traditional heparin-warfarin vs. direct oral anticoagulants (dabigatran, rivaroxaban, apixaban) (6 months) | Traditional heparin-warfarin (n = 100) | Direct oral anticoagulants (dabigatran, rivaroxaban, apixaban) (n = 19) | | |
| | | | Graft patency | 93% | 100% | n.s. |
| | | | Major adverse events | 0% | 0% | n.s. |
| | | | Bleeding events (hematoma) | 3% | 0% | n.s. |
| Logason [32], 2001/RCT | Venous and prosthetic grafts | Dextran 70 vs. LMWH (3 months) | Dextran 70 (total dose of 2,500 mL) (total grafts, n = 138; venous graft, n = 73; prosthetic graft, n = 65) | LMWH (40 mg s.c. eight doses) (total grafts, n = 131; venous graft, n = 68; prosthetic graft, n = 63) | | |
| | | | Graft patency | All graft | 88% | 83% | n.s. |
| | | | | Autogenous graft | 90% | 79% | n.s. |
| | | | | Prosthetic graft | 86% | 87% | n.s. |
| | | | | Death (all grafts) | 4% | 3% | n.s. |
| | | | | MACEs (all grafts) | 17% | 5% | P < 0.05 |
| | | | Bleeding events (all grafts) | 6.90% | 2.30% | n.s. |
| Samama [33], 1995/RCT | Venous and prosthetic grafts | Unfractionated heparin vs. LMWH (1 month) | Unfractionated heparin (50 IU/kg i.v. then 150 IU/kg s.c. twice a day for 10 days) (n = 100) | LMWH (75 IU/kg i.v. then 75 IU/kg s.c. twice a day for 10 days) (n = 99) | | |
| | | | Graft occlusion | 24% | 11% | P = 0.025 |

1) 100% below the knee bypass, 2) doses were not mentioned, 3) heparin started 24 h postoperatively and switch to warfarin was undertaken when INR was therapeutic

1) Dextran possesses antithrombotic and flow-promoting properties, 2) approximately 70% of the bypass grafts were below the knee

90% of the bypass grafts were below the knee
sugesting that MAPT suffices for these groups. However, DAPT in the form of aspirin + clopidogrel was effective over aspirin alone for prosthetic, but not venous graft. This superior effect was accompanied by the occurrence of non-severe and non-fatal albeit higher non-severe bleeding incidences, suggesting a potential benefit of this regime for below-knee prosthetic graft with required precaution. Also, AC or in combination with aspirin yielded superior results compared to AP alone following endovascular procedure, and bypass surgery for venous and prosthetic grafts, suggesting the benefit of this regime in the absence of contraindications.

Antithrombotic treatment for endovascular intervention for infrapopliteal artery

The benefits of post-endovascular intervention antiplatelet antithrombotic therapy for PAD in preventing cardiovascular complications are well known. Recommendations regarding the optimal regimen for patients with PAD including infrapopliteal disease are variable and inconsistent. For instance, the European Society of Cardiology (ESC) guidelines recommend MAPT: mono-antiplatelet treatment; DAPT: dual antiplatelet treatment; i.v.: intravenous; s.c.: subcutaneous; RCT: randomized control trial; INR: international normalized ratio; LMWH: low molecular weight heparin; MACEs: major adverse cardiac events; MCE: major cardiac event; PTFE: polytetrafluoroethylene; n.s.: not significant; n.m.: not mentioned; HR: hazard ratio; SE: standard error.

### Table 3. Antiplatelet and Anticoagulant Treatments Following Below-Knee Bypass Surgery - (continued)

| Study/type | Procedure | Treatment/follow-up duration | Endpoints | Treatment groups and endpoint rates | Significance | Notes |
|------------|-----------|------------------------------|-----------|------------------------------------|-------------|-------|
| LeCroy [34], 2005/retrospective | PTFE graft | Warfarin (subtherapeutic) vs. warfarin (therapeutic) (up to 5 years) | | Warfarin (subtherapeutic) (n = 40) vs. Warfarin (therapeutic) (n = 37) | | |
| | | | | | 1) Subtherapeutic INR (≤ 1.9), therapeutic INR (≥ 2.0), 2) median primary patency of 29.9 months (SE = 2.23) for therapeutic group vs. 6.8 months (SE = 2.34) for non-therapeutic group |
| | | | | | Patency | n.m. | n.s. |
| | | | | | Graft occlusion | 60% | 18.92% |
| | | | | | Bleeding events | 3% | 11% |
| | | | | | HR: hazard ratio; SE: standard error. |

MAPT: mono-antiplatelet treatment; DAPT: dual antiplatelet treatment; i.v.: intravenous; s.c.: subcutaneous; RCT: randomized control trial; INR: international normalized ratio; LMWH: low molecular weight heparin; MACEs: major adverse cardiac events; MCE: major cardiac event; PTFE: polytetrafluoroethylene; n.s.: not significant; n.m.: not mentioned; HR: hazard ratio; SE: standard error.
alone for infrapopliteal artery diseases. Interestingly, in one of the two studies, there were no significant differences for patency between the two treatment groups when the data were evaluated for PAD, but significant differences were monitored when data was stratified for infrapopliteal artery [26], further underscoring the importance of specifying treatments according to the injured artery segment. The Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial showed that the combined treatment with rivaroxaban and aspirin reduced the risk of acute limb ischemia, vascular amputation, and mortality, among others when compared to aspirin alone in patients with established vascular diseases [42]. Rivaroxaban and aspirin, however, increased bleeding events relative to aspirin alone although there were no significant effects for severe bleeding [42]. In accordance, Wang et al did not find significant differences in the bleeding events relative to aspirin alone although there were no significant effects for severe bleeding [42].

Collectively this data will not conclude changes to the current recommendation following endovascular intervention for PAD due to the lack of evidence to suggest otherwise. However, there was also no enough data to support current recommendations as well for infrapopliteal artery diseases. The combined treatment with AP + AC yielded promising results for the improvement of restenosis without the increase in bleeding events. More studies are warranted to establish the value and superiority of this treatment regime following endovascular intervention.

**Antithrombotic treatment for bypass surgery for infrapopliteal artery**

It has been reported that the patency rates for autologous distal bypass grafts are superior to those for prosthetic lower extremity bypass grafts [43-45]. Nonetheless, outcomes were comparable between the two groups when appropriate antithrombotic treatment was used following surgery [46]. The routine use of AP therapy for patients with PAD for bypass surgery has been mainly attributed to preserving the patency of the graft [43, 47]. The persistence of high levels of graft occlusion despite the use of MAPT [14, 15] has raised the question of modifying the treatment by adding AC or another AP.

Similar to antithrombotic treatment following endovascular therapy, recommendations for treatment following bypass surgery were also variable and without the presence of concrete evidences [35-38, 48]. The ESC guidelines include recommendation of the use of MAPT (aspirin) or DAPT (aspirin and dipyridamole) following bypass surgery (class I recommendations), vitamin K antagonists after venous infrainguinal bypass surgery, and DAPT (aspirin and clopidogrel) for below-knee prosthetic grafts (class IIb recommendations) [36, 37]. The American College of Chest Physicians recommendation includes the use of MAPT (aspirin or clopidogrel) following bypass surgery (grade 1A), and 1-year treatment with DAPT (aspirin and clopidogrel) for below-knee prosthetic grafts (grade 2C) [37, 38]. The Society for Vascular Surgery practice guidelines recommend the use of MAPT (aspirin or clopidogrel), or DAPT (aspirin and clopidogrel) for bypass surgery regardless of the graft type (grade 2B) [35, 37].

Clopidogrel, a thienopyridine derivative, has been thought as a strong candidate due to its significant effects on the improvement of cardiac parameters when combined with aspirin [49]. The clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial [28] showed that the combined effects of aspirin and clopidogrel were only significant over aspirin for graft occlusion and amputation when data were stratified for prosthetic grafts, further underscoring the importance of performing subgroup analysis for the data. Another thienopyridine derivative ticlopidine showed superior results when compared to placebo for graft restenosis and limb amputation [27]. Thus, the addition of thienopyridine derivative to aspirin (DAPT) might improve the outcome following bypass surgery, particularly for prosthetic grafts.

The combined treatment of warfarin and aspirin resulted in significant reduction in prosthetic femoropopliteal bypass graft failure compared to aspirin [50]. In agreement, similar results were reported for venous infrapopliteal bypass graft in high risk group patients [30]. Also, studies for infrapopliteal artery showed the importance of adjusting the levels warfarin to achieve therapeutic INR levels to significantly improve the patency and survival of the prosthetic grafts [34]. The improved survival rates in patients might be attributed to decreased thrombotic heart diseases [30]. Despite the clear advantage of warfarin, its use has been hindered by the reports of high bleeding events by the Dutch Bypass Oral Anticoagulants study [51]. However, increased bleeding events did not include significant increase in major or fatal bleeding, rather most of the bleeding cases were manageable [30, 34]. This data suggests that ACs, particularly for prosthetic grafts, and the addition of warfarin to MAPT might be prescribed to patient without indicated contraindication and more studies are warranted.

**Limitations**

There exists considerable heterogeneity in therapeutic regimen, data reporting, non-consistency in reporting outcomes, especially bleeding. Many of the data was reported in retrospective studies with the known risk of potential bias. The numbers of studies, patients, endovascular or surgical intervention, and follow-up duration included in the treatment-specific statistical analyses varied across the studies in same treatment groups. Studies that compare DAPT to ACs are not available. Also, many of commonly used APs and ACs are not covered in the literature of infrapopliteal artery diseases. Finally, the review included data from studies published over an extended duration of time (over 10 years); various aspects of these endovascular interventions as well as bypass surgery may have evolved to some extent during this time, thereby affecting outcomes.

**Conclusions**

Antithrombotic treatments, especially regimens that combine
APs and ACs, improve patient outcomes following endovascular intervention and bypass surgery for infrapopliteal artery disease. Further prospective randomized trials with long duration of follow-up are needed to determine the ideal antithrombotic therapy, evaluate the sufficiency of MAPT following endovascular intervention, and to validate the efficacy and safety of the combined AP + AC for this group of patients, particularly high risk patients such as those with history of endovascular intervention or bypass failure.

Acknowledgments

The authors acknowledge Superior Medical Experts for research and editing assistance.

Financial Disclosure

None to declare.

Conflict of Interest

None to declare.

Author Contributions

AG contributed to the conception and design of the work; AG and KG contributed to the literature search, data analysis for the work, and drafting the manuscript; MSL, VK and SR critically revised the manuscript.

References

1. Jakob T, Nordmann AJ, Schandelmaier S, Ferreira-Gonzalez I, Briel M. Fibrates for primary prevention of cardiovascular disease events. Cochrane Database Syst Rev. 2016;11:CD009753.

2. Mahe G, Kaladji A, Le Faucheur A, Jaquinandi V. Internal iliac artery disease management: still absent in the update to TASC II (Inter-Society consensus for the management of peripheral arterial disease). J Endovasc Ther. 2016;23(1):233-234.

3. Rooke TW, Hirsch AT, Misra S, Sidawy AN, Beckman JA, Findeiss L, Golzarian J, et al. Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA Guideline Recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61(14):1555-1570.

4. Graziani L, Silvestro A, Bertone V, Manara E, Andreini R, Sigala A, Mingardi R, et al. Vascular involvement in diabetic subjects with ischemic foot ulcer: a new morphologic categorization of disease severity. Eur J Vasc Endovasc Surg. 2007;33(4):453-460.

5. Jones WS, Mi X, Qualls LG, Vemulpalli S, Peterson ED, Patel MR, Curtis LH. Trends in settings for peripheral vascular intervention and the effect of changes in the outpatient prospective payment system. J Am Coll Cardiol. 2015;65(9):920-927.

6. Hong MS, Beck AW, Nelson PR. Emerging national trends in the management and outcomes of lower extremity peripheral arterial disease. Ann Vasc Surg. 2011;25(1):44-54.

7. Aboyans V, Criqui MH, Denenberg JO, Knoke JD, Ridker PM, Fronek A. Risk factors for progression of peripheral arterial disease in large and small vessels. Circulation. 2006;113(22):2623-2629.

8. Schillinger M, Haumer M, Schlerka G, Mlekusch W, Exner M, Ahmadi R, Minar E. Restenosis after percutaneous transluminal angioplasty in the femoropopliteal segment: the role of inflammation. J Endovasc Ther. 2001;8(5):477-483.

9. Jamsen T, Manninen H, Tulla H, Matsu P. The final outcome of primary infrainguinal percutaneous transluminal angioplasty in 100 consecutive patients with chronic critical limb ischemia. J Vasc Interv Radiol. 2002;13(5):455-463.

10. Schillinger M, Exner M, Mlekusch W, Rumpold H, Ahmadi R, Subeti S, Haumer M, et al. Vascular inflammation and percutaneous transluminal angioplasty of the femoropopliteal artery: association with restenosis. Radiology. 2002;225(1):21-26.

11. Baumann F, Willenberg T, Do DD, Keo HH, Baumgartner I, Dielm N. Endovascular revascularization of below-the-knee arteries: prospective short-term angiographic and clinical follow-up. J Vasc Interv Radiol. 2011;22(12):1665-1673.

12. Iida O, Soga Y, Kawasaki D, Hirano K, Yamaoka T, Suzuki K, Miyashita Y, et al. Angiographic restenosis and its clinical impact after infrapopliteal angioplasty. Eur J Vasc Endovasc Surg. 2012;44(4):425-431.

13. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, TASC II Working Group. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007;45(Suppl S):S5-S7.

14. Mills JL. Mechanisms of vein graft failure: the location, distribution, and characteristics of lesions that predispose to graft failure. Semin Vasc Surg. 1993;6(2):78-91.

15. Brittenden J, Bradbury AW. The durability of iliac and femoral angioplasty. In: The Durability of Vascular and Endovascular Surgery. W B Saunders Company; 1999.

16. Mannava K, Money SR. Current management of peripheral arterial occlusive disease: a review of pharmacologic agents and other interventions. Am J Cardiovasc Drugs. 2007;7(1):59-66.

17. Iida O, Nanto S, Uematsu M, Morozumi T, Kotani J, Awata M, Onishi T, et al. Cilostazol reduces target lesion revascularization after percutaneous transluminal angioplasty in the femoropopliteal artery. Circ J. 2005;69(10):1256-1259.

18. The Methods and Applications of Skin Grafting. Hospital (Lond 1886). 1893;14(350):170-172.

19. Laird JR, Schneider PA, Tepe G, Brodmann M, Zeller T,
Metzger C, Krishnan P, et al. Durability of treatment effect using a drug-coated balloon for femoropopliteal lesions: 24-month results of IN.PACT SFA. J Am Coll Cardiol. 2015;66(21):2329-2338.

20. Li J, Karim A, Shishehbor MH. The use of drug-coated balloons in the treatment of femoropopliteal and infrapopliteal disease. J Cardiovasc Surg (Torino). 2018;59(4):512-525.

21. Nehler MR, Brass EP, Anthony R, Dormandy J, Jiao J, Karim A, Shishehbor MH. The use of drug-coated balloons in the treatment of femoropopliteal and infrapopliteal disease. J Cardiovasc Surg (Torino). 2018;59(4):512-525.

22. Soga Y, Iida O, Kawasaki D, Hirano K, Yamaoka T, Suzuki K. Impact of cilostazol on angiographic restenosis after balloon angioplasty for infrapopliteal artery disease in patients with critical limb ischemia. J Bras Endovasc Surg. 2012;44(6):577-581.

23. Soga Y, Takahara M, Iida O, Yamauchi Y, Hirano K, Fukunaga M, Zen K, et al. Efficacy of Cilostazol for Below-the-Knee Artery Disease after Balloon Angioplasty in Patients with Severe Limb Ischemia (CABBAGE Trial). Ann Vasc Surg. 2017;45:22-28.

24. Lejay A, Thaveau F, Aleib B, Geny B, Kretz JG, Stephan D, Chakne N. Platelet antiaggregation therapy and subinguinal endovascular revascularization. Ann Vasc Surg. 2013;27(5):621-626.

25. Wang J, Zhu YQ, Liu F, Li MH, Zhao JG, Tan HQ, Wang JB, et al. Batroxobin for prevention of restenosis in diabetic patients after infrapopliteal arterial angioplasty: a small randomized pilot trial. Ann Vasc Surg. 2010;24(7):876-884.

26. Wang J, Zhu YQ, Li MH, Zhao JG, Tan HQ, Wang JB, Liu F, et al. Batroxobin plus aspirin reduces restenosis after angioplasty for arterial occlusive disease in diabetic patients with lower-limb ischemia. J Vasc Interv Radiol. 2011;22(7):987-994.

27. Becquemin JP. Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs. Etude de la Ticlopidine apres Pontage Femoro-Poplite et de la Ticlopidine apres Pontage Femoro-Poplite and the Association Universitaire de Recherche en Chirurgie. N Engl J Med. 1997;337(24):1726-1731.

28. Belch JJ, Dormandy J, Committee CW, Biasi GM, Cairrols M, Diehm C, Elkboom B, et al. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg. 2010;52(4):825-833, e821-822.

29. Clyne CA, Archer TJ, Atuahire TK, Chant AD, Webster JH. Random control trial of a short course of aspirin and dipiridamole (Persantin) for femorodistal grafts. Br J Surg. 1987;74(4):246-248.

30. Sarac TP, Huber TS, Back MR, Ozaki CK, Carlton LM, Flynn TC, Seeger JM. Warfarin improves the outcome of infranigual vein bypass grafting at high risk for failure. J Vasc Surg. 1998;28(3):446-457.

31. Aurschina A, Kibrik P, Eisenberg J, Alsheekh A, Hingorani A, Marks N, Ascher E. Clinical outcomes of direct oral anticoagulants after lower extremity arterial procedures. Vascular. 2018;26(2):189-193.

32. Logason K, Bergqvist D, Study Group on Antithrombotic Prophylaxis of Femorodistal Bypass S. Low molecular weight heparin (enoxaparin) versus dextran in the prevention of early occlusion following arterial bypass surgery distal to the groin. Eur J Vasc Endovasc Surg. 2001;21(3):261-265.

33. Samama CM, Gigou F, Ill P. Low-molecular-weight heparin vs. unfractionated heparin in femorodistal reconstructive surgery: a multicenter open randomized study. Enoxart Study Group. Ann Vasc Surg. 1995;9(Suppl):S45-53.

34. LeCroy CJ, Patterson MA, Taylor SM, Westfall AO, Jordan WD, Jr. Effect of warfarin anticoagulation on below-knee polytetrafluoroethylene graft patency. Ann Vasc Surg. 2005;19(2):192-198.

35. Society for Vascular Surgery Lower Extremity Guidelines Writing Group, Conte MS, Pomposelli FB, Clair DG, Geraghty PJ, McKinsey JF, Mills JL, et al. Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication. J Vasc Surg. 2015;61(3 Suppl):S2-S41S.

36. European Stroke O, Tendera M, Aboyans V, Bartelink M., Baumgartner I, Clement D, Collet JP, et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(22):2851-2906.

37. Hess CN, Norgren L, Ansel GM, Capell WH, Fletcher JP, Fowkes FGR, Gottsater A, et al. A structured review of antithrombotic therapy in peripheral artery disease with a focus on revascularization: A TASC (InterSociety Consensus for the Management of Peripheral Artery Disease) initiative. Circulation. 2017;135(25):2534-2555.

38. Alonso-Coello P, Bellmunt S, McGorrian C, Anand SS, Guzman R, Criqui MH, Akk EA, et al. Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e669S-e690S.

39. Tomoi Y, Soga Y, Iida O, Fujihara M, Ando K. Impact of cilostazol on angiographic restenosis after balloon angioplasty for femoropopliteal in-stent restenosis. J Endovasc Ther. 2017;24(5):640-646.

40. Kostiu EP. [Ratio of somatostatin-glucagon secretion in diabetes mellitus]. Fiziol Zh. 1985;31(2):195-201.

41. Olinic DM, Tataru DA, Homorodean C, Anand SS. Guzman R, Criqui MH, Akl EA, et al. Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e669S-e690S.

42. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, et al. Rivaroxaban plus aspirin in patients with lower-limb ischemia. J Vasc Interv Radiol. 2013;27(5):987-994.

43. Batroxobin for prevention of restenosis after angioplasty for arterial occlusive disease in diabetic patients with lower-limb ischemia. J Vasc Interv Radiol. 2011;22(7):987-994.

44. Becquemin JP. Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs. Etude de la Ticlopidine apres Pontage Femoro-Poplite and the Association Universitaire de Recherche en Chirurgie. N Engl J Med. 1997;337(24):1726-1731.

45. Belch JJ, Dormandy J, Committee CW, Biasi GM, Cairrols M, Diehm C, Elkboom B, et al. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg. 2010;52(4):825-833, e821-822.

46. Clyne CA, Archer TJ, Atuahire TK, Chant AD, Webster JH. Random control trial of a short course of aspirin and dipiridamole (Persantin) for femorodistal grafts. Br J Surg. 1987;74(4):246-248.

47. Sarac TP, Huber TS, Back MR, Ozaki CK, Carlton LM, Flynn TC, Seeger JM. Warfarin improves the outcome of infranigual vein bypass grafting at high risk for failure. J Vasc Surg. 1998;28(3):446-457.
44. Veith FJ, Gupta SK, Ascer E, White-Flores S, Samson RH, Scher LA, Towne JB, et al. Six-year prospective multicenter randomized comparison of autologous saphenous vein and expanded polytetrafluoroethylene grafts in infrainguinal arterial reconstructions. J Vasc Surg. 1986;3(1):104-114.

45. Wixon CL, Mills JL, Westerband A, Hughes JD, Ihnat DM. An economic appraisal of lower extremity bypass graft maintenance. J Vasc Surg. 2000;32(1):1-12.

46. Suckow BD, Kraiss LW, Stone DH, Schanzer A, Bertges DJ, Baril DT, Cronenwett JL, et al. Comparison of graft patency, limb salvage, and antithrombotic therapy between prosthetic and autogenous below-knee bypass for critical limb ischemia. Ann Vasc Surg. 2013;27(8):1134-1145.

47. Geraghty AJ, Welch K. Antithrombotic agents for preventing thrombosis after infrainguinal arterial bypass surgery. Cochrane Database Syst Rev. 2011;6:CD000536.

48. Brown GP, Iwamoto GK, Monick MM, Hunninghake GW. Cigarette smoking decreases interleukin 1 release by human alveolar macrophages. Am J Physiol. 1989;256(2 Pt 1):C260-264.

49. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, Collins R, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366(9497):1607-1621.

50. Jackson MR, Johnson WC, Williford WO, Valentine RJ, Cloggett GP. The effect of anticoagulation therapy and graft selection on the ischemic consequences of femoropopliteal bypass graft occlusion: results from a multicenter randomized clinical trial. J Vasc Surg. 2002;35(2):292-298.

51. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial. Lancet. 2000;355(9201):346-351.